• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CAMPTOTHECIN Drug Record

  • Summary
  • Interactions
  • Claims
  • CAMPTOTHECIN chembl:CHEMBL65 Antineoplastic

    Alternate Names:

    NSC-94600
    CPT
    (+)-CAMPTOTHECINE
    (S)-CAMPTOTHECIN
    20(S)-CAMPTOTHECIN
    (+)-CAMPTOTHECIN
    20(S)-CAMPTOTHECINE
    21,22-SECOCAMPTOTHECIN-21-OIC ACID LACTONE
    CAMPTOTHECIN
    CAMPTOTHECINE
    D-CAMPTOTHECIN
    (S)-(+)-CAMPTOTHECIN
    drugbank:04690
    chemidplus:7689-03-4
    chembl:CHEMBL65
    pubchem.compound:24360

    Drug Info:

    FDA Approval approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    Drug Categories topoisomerase i inhibitors
    Drug Categories p-glycoprotein substrates
    (4 More Sources)

    Publications:

    Costa-Pereira et al., 2000, Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis., Br. J. Cancer
    Shih et al., 2005, Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells., Cancer Res.
    Dong G et al., 2010, Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents., J Med Chem
    Kamal A et al., 2013, 4β-[4'-(1-(Aryl)ureido)benzamide]podophyllotoxins as DNA topoisomerase I and IIα inhibitors and apoptosis inducing agents., Bioorg Med Chem
    Shchekotikhin AE et al., 2014, Synthesis and evaluation of new antitumor 3-aminomethyl-4,11-dihydroxynaphtho[2,3-f]indole-5,10-diones., Eur J Med Chem
    Song Y et al., 2010, Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors., J Med Chem
    Wu WB et al., 2011, Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors., Eur J Med Chem
    Khadka DB et al., 2011, 3-Arylisoquinolines as novel topoisomerase I inhibitors., Bioorg Med Chem
    D'yakonov VA et al., 2015, Stereoselective synthesis of 11-phenylundeca-5Z,9Z-dienoic acid and investigation of its human topoisomerase I and IIα inhibitory activity., Bioorg Med Chem Lett
    Chen TC et al., 2015, Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents., Eur J Med Chem
    Lemster T et al., 2009, Photochemical electrocyclisation of 3-vinylindoles to pyrido[2,3-a]-, pyrido[4,3-a]- and thieno[2,3-a]-carbazoles: design, synthesis, DNA binding and antitumor cell cytotoxicity., Eur J Med Chem
    Verones V et al., 2013, Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives., Eur J Med Chem
    Racané L et al., 2013, New anticancer active and selective phenylene-bisbenzothiazoles: synthesis, antiproliferative evaluation and DNA binding., Eur J Med Chem
    Wang MJ et al., 2014, Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents., J Med Chem
    Parrino B et al., 2014, 11H-Pyrido[3',2':4,5]pyrrolo[3,2-c]cinnoline and pyrido[3',2':4,5]pyrrolo[1,2-c][1,2,3]benzotriazine: two new ring systems with antitumor activity., J Med Chem
    Fan Y et al., 1998, Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin., J Med Chem
    Oppegard LM et al., 2012, Inhibition of human topoisomerases I and II by simocyclinone D8., J Nat Prod
    Luo Y et al., 2012, Synthesis and biological evaluation of new homocamptothecin analogs., Eur J Med Chem
    Kiselev E et al., 2014, Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells., J Med Chem
    Cinelli MA et al., 2010, The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode., Bioorg Med Chem
    Shchekotikhin AE et al., 2007, Naphthoindole-based analogues of tryptophan and tryptamine: synthesis and cytotoxic properties., Bioorg Med Chem
    Bar FM et al., 2009, Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors., J Nat Prod
    Christodoulou MS et al., 2013, Quinazolinecarboline alkaloid evodiamine as scaffold for targeting topoisomerase I and sirtuins., Bioorg Med Chem
    Christodoulou MS et al., 2015, Boehmeriasin A as new lead compound for the inhibition of topoisomerases and SIRT2., Eur J Med Chem
    You QD et al., 2009, Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification., J Med Chem
    Nagarajan M et al., 2004, Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings., J Med Chem
    Evdokimov NM et al., 2011, Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents., J Med Chem
    Kiselev E et al., 2012, Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents: a systematic study of structure-activity relationships., J Med Chem
    Negi A et al., 2015, Imine/amide-imidazole conjugates derived from 5-amino-4-cyano-N1-substituted benzyl imidazole: Microwave-assisted synthesis and anticancer activity via selective topoisomerase-II-α inhibition., Bioorg Med Chem
    Van HT et al., 2007, Convenient synthesis of indeno[1,2-c]isoquinolines as constrained forms of 3-arylisoquinolines and docking study of a topoisomerase I inhibitor into DNA-topoisomerase I complex., Bioorg Med Chem Lett
    He S et al., 2015, Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors., ACS Med Chem Lett
    Cinelli MA et al., 2009, Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships., Bioorg Med Chem
    Majumdar P et al., 2015, Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity., Eur J Med Chem
    Lee CC et al., 2013, Design, synthesis and antiproliferative evaluation of fluorenone analogs with DNA topoisomerase I inhibitory properties., Bioorg Med Chem
    Santos RC et al., 2010, Synthesis and structure-activity relationship study of novel cytotoxic carbamate and N-acylheterocyclic bearing derivatives of betulin and betulinic acid., Bioorg Med Chem
    Hecht SM et al., 1992, A strategy for identifying novel, mechanistically unique inhibitors of topoisomerase I., J Nat Prod
    Zhou BN et al., 2000, Use of COMPARE analysis to discover new natural product drugs: isolation of camptothecin and 9-methoxycamptothecin from a new source., J Nat Prod
    Dong G et al., 2012, New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations., J Med Chem
    Kashyap M et al., 2013, Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents., Bioorg Med Chem Lett
    Masurier N et al., 2012, Imidazonaphthyridine systems (part 2): Functionalization of the phenyl ring linked to the pyridine pharmacophore and its replacement by a pyridinone ring produces intriguing differences in cytocidal activity., Eur J Med Chem
    Wang L et al., 2014, Suzuki coupling based synthesis and in vitro cytotoxic evaluation of 7-heteroaryl-substituted camptothecin analogs., Bioorg Med Chem Lett
    Beck DE et al., 2015, Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore., J Med Chem
    Taliani S et al., 2013, Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors., J Med Chem
    Di Salvo A et al., 2013, Synthesis, cytotoxicity and DNA binding of oxoazabenzo[de]anthracenes derivatives in colon cancer Caco-2 cells., Eur J Med Chem
    Kiselev E et al., 2011, 7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents., J Med Chem
    Chen CL et al., 2014, Ring fusion strategy for the synthesis of anthra[2,3-d]oxazole-2-thione-5,10-dione homologues as DNA topoisomerase inhibitors and as antitumor agents., Eur J Med Chem
    Sović I et al., 2014, Novel phenyl and pyridyl substituted derivatives of isoindolines: Synthesis, antitumor activity and DNA binding features., Eur J Med Chem
    Baviskar AT et al., 2013, Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity., Bioorg Med Chem
    Teicher, 2008, Next generation topoisomerase I inhibitors: Rationale and biomarker strategies., Biochem. Pharmacol.
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    van der Merwe et al., 2008, Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin., J. Biol. Chem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Manita D et al., 2011, Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction., Bioorg Med Chem
    Goldwasser et al., 1996, Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines., Oncol. Res.
    Rajule R et al., 2012, Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study., Bioorg Med Chem
    Muscarella et al., 2003, Cross-linking of surface IgM in the Burkitt's lymphoma cell line ST486 provides protection against arsenite- and stress-induced apoptosis that is mediated by ERK and phosphoinositide 3-kinase signaling pathways., J. Biol. Chem.
    Chu et al., 1999, Active efflux of CPT-11 and its metabolites in human KB-derived cell lines., J. Pharmacol. Exp. Ther.
    Ahmed et al., 2013, Epigenetic and genetic features of 24 colon cancer cell lines., Oncogenesis
    Song et al., 2015, Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Wang et al., 2004, Involvement of Hus1 in the chain elongation step of DNA replication after exposure to camptothecin or ionizing radiation., Nucleic Acids Res.
    Nair et al., Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines., Anticancer Res.
    Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.
    Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science
    Yasui et al., 2004, Alteration in copy numbers of genes as a mechanism for acquired drug resistance., Cancer Res.
    Hong et al., 2004, Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model., World J. Gastroenterol.
    Yamaguchi et al., 2005, Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death., Oncol. Rep.
    Weller et al., 1997, Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone., Int. J. Cancer
    Otsuki et al., 2007, WRN counteracts the NHEJ pathway upon camptothecin exposure., Biochem. Biophys. Res. Commun.
    Lin et al., 1998, Camptothecin induces differentiation, tissue transglutaminase and apoptosis in cultured keratinocytes., Exp. Dermatol.
    Park et al., 2000, Involvement of retinoblastoma family members and E2F/DP complexes in the death of neurons evoked by DNA damage., J. Neurosci.
    Hetman et al., 1999, Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase., J. Biol. Chem.
    Ishii et al., 2004, GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells., Cancer Lett.
    Jakob et al., 1994, Topoisomerase I-inhibition enhances vitamin D-responsive expression of the receptor for lipopolysaccharide binding protein CD 14., Biochem. Biophys. Res. Commun.
    Kuo et al., 2006, DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors., J. Pharmacol. Exp. Ther.
    Rath et al., 2006, The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells., Biochim. Biophys. Acta
  • CAMPTOTHECIN   HUS1

    Interaction Score: 3.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14762204


    Sources:
    NCI

  • CAMPTOTHECIN   HNRNPA1

    Interaction Score: 3.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22071521


    Sources:
    DTC

  • CAMPTOTHECIN   TOP1

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name XMT-1001
    Novel drug target Established target

    PMIDs:
    20942490 23849207 25244612 20155916 21600681 21095131 25913198 25799376 19386396 23202849 23603616 25003995 25317694 9632354 22867097 22647222 24502276 20630766 17276690 19691293 24103429 25626146 19715319 15509164 21388138 22329436 26216018 17827007 25815139 19783447 26312433 24094433 20494586 1324981 11000035 22867019 23321564 22503207 24529870 25909279 23987476 24099994 21823606 25240093 25282261 23920485 18061144 10592235 18056711 11752352


    Sources:
    DTC DrugBank TdgClinicalTrial ClearityFoundationClinicalTrial TTD

  • CAMPTOTHECIN   XRCC5

    Interaction Score: 0.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16230379


    Sources:
    NCI

  • CAMPTOTHECIN   STAG2

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Camptothecin + Olaparib
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    24356817 21852505


    Sources:
    JAX-CKB

  • CAMPTOTHECIN   THBS1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16962673


    Sources:
    NCI

  • CAMPTOTHECIN   COL18A1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15069724


    Sources:
    NCI

  • CAMPTOTHECIN   DCK

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14973057


    Sources:
    NCI

  • CAMPTOTHECIN   TGM2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9758415


    Sources:
    NCI

  • CAMPTOTHECIN   MCL1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8938795 22386982


    Sources:
    DTC NCI

  • CAMPTOTHECIN   MGMT

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16258022


    Sources:
    NCI

  • CAMPTOTHECIN   CDK4

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10777774


    Sources:
    NCI

  • CAMPTOTHECIN   MAPK9

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10839298


    Sources:
    NCI

  • CAMPTOTHECIN   BIRC5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16211302


    Sources:
    NCI

  • CAMPTOTHECIN   BAX

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9398050


    Sources:
    NCI

  • CAMPTOTHECIN   GSTP1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15500952


    Sources:
    NCI

  • CAMPTOTHECIN   PIK3CA

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gedatolisib + Camptothecin
    Indication/Tumor Type colon cancer
    Response Type sensitive

    PMIDs:
    12464623 24042735 25688157


    Sources:
    JAX-CKB NCI

  • CAMPTOTHECIN   PIK3CB

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12464623


    Sources:
    NCI

  • CAMPTOTHECIN   BDNF

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10428835


    Sources:
    NCI

  • CAMPTOTHECIN   HBB

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAMPTOTHECIN   WRN

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17303082


    Sources:
    NCI

  • CAMPTOTHECIN   KRAS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gedatolisib + Camptothecin
    Indication/Tumor Type colon cancer
    Response Type sensitive

    PMIDs:
    24042735 25688157


    Sources:
    JAX-CKB

  • CAMPTOTHECIN   TOP2A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11205246


    Sources:
    NCI

  • CAMPTOTHECIN   THPO

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAMPTOTHECIN   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9918583


    Sources:
    NCI

  • CAMPTOTHECIN   MTOR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAMPTOTHECIN   HIF1A

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAMPTOTHECIN   VDR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7510956


    Sources:
    NCI

  • CAMPTOTHECIN   ATXN2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAMPTOTHECIN   ATAD5

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAMPTOTHECIN   HSD17B10

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAMPTOTHECIN   CYP2C19

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAMPTOTHECIN   CYP1A2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAMPTOTHECIN   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAMPTOTHECIN   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAMPTOTHECIN   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DrugBank: DB04690

    • Version: 5.1.7

    Alternate Names:
    7689-03-4 CAS Number
    CHEMBL65 ChEMBL ID

    Drug Info:
    Drug Type small molecule
    Drug Groups experimental
    Drug Categories alkaloids

    Publications:
    van der Merwe et al., 2008, Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin., J. Biol. Chem.
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

  • TdgClinicalTrial: CAMPTOTHECIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval approved

    Publications:

  • DTC: CAMPTOTHECIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL65 ChEMBL Drug ID

    Drug Info:

    Publications:
    Baviskar AT et al., 2013, Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity., Bioorg Med Chem
    Sović I et al., 2014, Novel phenyl and pyridyl substituted derivatives of isoindolines: Synthesis, antitumor activity and DNA binding features., Eur J Med Chem
    Chen CL et al., 2014, Ring fusion strategy for the synthesis of anthra[2,3-d]oxazole-2-thione-5,10-dione homologues as DNA topoisomerase inhibitors and as antitumor agents., Eur J Med Chem

  • NCI: CAMPTOTHECIN

    • Version: 14-September-2017

    Alternate Names:
    C338 NCI drug code

    Drug Info:

    Publications:
    Costa-Pereira et al., 2000, Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis., Br. J. Cancer
    Shih et al., 2005, Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells., Cancer Res.
    Goldwasser et al., 1996, Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines., Oncol. Res.

  • JAX-CKB: Camptothecin

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Song et al., 2015, Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Ahmed et al., 2013, Epigenetic and genetic features of 24 colon cancer cell lines., Oncogenesis
    Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science

  • TTD: Camptothecin

    • Version: 2020.06.01

    Alternate Names:
    D09YDM TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL65

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: CAMPTOTHECIN

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21